Roche ends the 30-year US hiatus in new stroke drugs
Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ago. Fibrin-specific plasminogen activator TNKase ( …